Related Experiment Video

Updated: Jun 22, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

[Role of anidulafungin in solid organ transplant recipients]

José M Aguado1, Josefina Ayats

  • 1Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Madrid, España. jaguadog@medynet.com

Enfermedades Infecciosas Y Microbiologia Clinica
|July 3, 2009
PubMed

Insights

Anidulafungin, a new antifungal, shows promise for preventing and treating invasive fungal infections in solid organ transplant recipients. It offers broad-spectrum activity and a favorable safety profile, requiring no dose adjustments for kidney or liver issues.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Transplantation Medicine

Background:

  • Solid organ transplant recipients face significant risks of invasive fungal infections (IFIs), with mortality rates ranging from 25% to 80%.
  • Candida species are the most common pathogens, followed by Aspergillus and Cryptococcus species.
  • Identifying risk factors allows for targeted antifungal prophylaxis in high-risk patients.

Purpose of the Study:

  • To evaluate the potential of anidulafungin, a novel echinocandin antifungal agent, for the treatment and prophylaxis of IFIs in solid organ transplant recipients.
  • To compare the efficacy and safety profile of anidulafungin with existing antifungal agents like caspofungin.

Main Methods:

  • In vitro assessment of anidulafungin's antifungal activity against relevant fungal pathogens, including Candida and Aspergillus species.
  • Review of pharmacokinetic and pharmacodynamic properties, focusing on metabolism and elimination pathways in the context of transplant patient comorbidities.
  • Analysis of potential drug interactions with common immunosuppressive agents used in solid organ transplantation.

Main Results:

  • Anidulafungin demonstrates broad-spectrum in vitro activity against Candida and Aspergillus species.
  • The drug is not metabolized by or eliminated through the kidneys, eliminating the need for dosage adjustments in patients with renal impairment.
  • Anidulafungin is not metabolized in the liver, minimizing the risk of drug-drug interactions with commonly used immunosuppressants and avoiding dose adjustments in patients with liver disease.

Conclusions:

  • Anidulafungin presents a favorable profile for managing IFIs in solid organ transplant recipients due to its broad spectrum of activity and advantageous pharmacokinetic properties.
  • Its lack of renal or hepatic metabolism simplifies dosing in a patient population often experiencing organ dysfunction and polypharmacy.
  • Anidulafungin is poised to be a valuable therapeutic option for IFIs in this vulnerable patient group, despite limited clinical experience to date.

More Related Videos

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model06:02

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model

Published on: November 6, 2020

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).